{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:19:49Z","timestamp":1784823589424,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.beha.2021.101249","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:41:59Z","timestamp":1612658519000},"page":"101249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Robert P.","family":"Hasserjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2021.101249_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101249_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2021.101249_bib6","series-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","year":"2001"},{"issue":"8","key":"10.1016\/j.beha.2021.101249_bib7","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy","volume":"90","author":"Estey","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101249_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002770050320","article-title":"Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia","volume":"75","author":"Kahl","year":"1997","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2021.101249_bib9","series-title":"WHO classificationi of tumours of haematopoietic and lymphoid tissues","year":"2008"},{"issue":"5","key":"10.1016\/j.beha.2021.101249_bib10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101249_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2021.101249_bib12","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101249_bib13","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/sj.leu.2403458","article-title":"A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication","volume":"18","author":"Kussick","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2021.101249_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2021.101249_bib15","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2021.101249_bib16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/modpathol.2016.118","article-title":"Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"issue":"24","key":"10.1016\/j.beha.2021.101249_bib17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101249_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101249_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V96.1.372","article-title":"Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia","volume":"96","author":"Albitar","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101249_bib20","doi-asserted-by":"crossref","first-page":"E193","DOI":"10.1002\/ajh.23808","article-title":"De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with >\/=30% blasts in older adults: a Bone Marrow Pathology Group study","volume":"89","author":"Hasserjian","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2021.101249_bib22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2021.101249_bib23","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.beha.2021.101249_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.25814","article-title":"Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a bone marrow pathology group study","volume":"95","author":"Rogers","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2021.101249_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.genom.3.032802.115046","article-title":"Genetics of myeloid leukemias","volume":"3","author":"Kelly","year":"2002","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"12","key":"10.1016\/j.beha.2021.101249_bib26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2021.101249_bib27","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2012.071449","article-title":"Reproducibility of the World Health organization 2008 criteria for myelodysplastic syndromes","volume":"98","author":"Senent","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.beha.2021.101249_bib29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2021.101249_bib30","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin Canc Res"},{"issue":"1","key":"10.1016\/j.beha.2021.101249_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Canc Cell"},{"issue":"5","key":"10.1016\/j.beha.2021.101249_bib32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/ajcp\/aqz206","article-title":"Genetic factors in acute myeloid leukemia with myelodysplasia-related changes","volume":"153","author":"Fang","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.beha.2021.101249_bib33","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101249_bib34","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.leukres.2015.06.012","article-title":"Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia","volume":"39","author":"Huck","year":"2015","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2021.101249_bib35","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.25769","article-title":"Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy","volume":"95","author":"Montalban-Bravo","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2021.101249_bib36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.exphem.2015.06.003","article-title":"Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia","volume":"43","author":"Mannelli","year":"2015","journal-title":"Exp Hematol"},{"issue":"10","key":"10.1016\/j.beha.2021.101249_bib37","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","article-title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes","volume":"6","author":"Devillier","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.beha.2021.101249_bib38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00277-014-2100-6","article-title":"Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1","volume":"93","author":"Rozman","year":"2014","journal-title":"Ann Hematol"},{"issue":"20","key":"10.1016\/j.beha.2021.101249_bib39","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/blood-2011-12-395574","article-title":"Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity","volume":"119","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2021.101249_bib40","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"Miesner","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101249_bib41","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system","volume":"113","author":"Weinberg","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2017.181842","article-title":"Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities","volume":"103","author":"Weinberg","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2021.101249_bib43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7540","key":"10.1016\/j.beha.2021.101249_bib44","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.beha.2021.101249_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.beha.2021.101249_bib46","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1200\/JCO.2011.38.7340","article-title":"Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms","volume":"30","author":"Nardi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib47","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3109\/10428194.2014.946023","article-title":"Myeloid neoplasms after breast cancer: \"therapy-related\" not an independent poor prognostic factor","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.beha.2021.101249_bib48","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2021.101249_bib49","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO.2011.41.1215","article-title":"Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms","volume":"30","author":"Larson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2021.101249_bib50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.humpath.2019.04.020","article-title":"Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA","volume":"90","author":"Kansal","year":"2019","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.beha.2021.101249_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3343\/alm.2019.39.3.311","article-title":"Reclassification of acute myeloid leukemia according to the 2016 WHO classification","volume":"39","author":"Jung","year":"2019","journal-title":"Ann Lab Med"},{"issue":"6","key":"10.1016\/j.beha.2021.101249_bib52","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/leu.2011.48","article-title":"Gene expression profiling in MDS and AML: potential and future avenues","volume":"25","author":"Theilgaard-Monch","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2021.101249_bib53","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2006-10-049783","article-title":"Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia","volume":"110","author":"Bullinger","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101249_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41375-018-0165-2","article-title":"Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association","volume":"33","author":"Gebhard","year":"2019","journal-title":"Leukemia"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:47Z","timestamp":1761498407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1521692621000104"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101249","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101249"}}